Yazici Halil, Oto Ozgur Akin, Mirioglu Safak, Dirim Ahmet Burak, Demir Erol, Uludag Omer, Akardere Omer Faruk, Caliskan Yasar, Lentine Krista L
Division of Nephrology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Division of Nephrology, Bezmialem Vakif University School of Medicine, Istanbul, Turkey.
Rev Nefrol Dial Transpl. 2023 Jul-Sep;43(3):156-166. Epub 2023 Sep 14.
Prophylactic acid suppression with proton pump inhibitors or H2 receptor antagonists is often administered after kidney transplantation. The Association of proton pump inhibitors or H2 receptor antagonists with acute rejection, hypomagnesemia, and graft loss in kidney transplant recipients is not well established.
We performed a retrospective cohort study of 302 kidney transplant recipients at one center (57% male; mean age 35.5±11.2 years) with more than 6 months post-transplant follow-up. Recipients were grouped according to gastric acid prophylaxis: only proton pump inhibitors (n=179), only H2 receptor antagonists (n=42), proton pump inhibitors and H2 receptor antagonists (n=55), and nonusers (n=26). The primary outcome was biopsy-proven acute rejection. Graft loss and hypomagnesemia were defined as secondary outcomes.
Nonusers were younger and mostly under steroid-free immunosuppression compared to other study groups (p=0.030 and p=0.009, respectively). The primary outcome was similar across study groups (p=0.266). Kaplan-Meier analyses also demonstrated similar 10-year graft survival rates: 95.5% for proton pump inhibitors, 97.6% for H2 receptor antagonists, 100% for proton pump inhibitors/H2 receptor antagonists, and 96.2% for nonusers (p=0.275).
The use of proton pump inhibitors is not associated with acute rejection or graft loss but may cause mild hypomagnesemia in kidney transplant recipients.
肾移植术后常使用质子泵抑制剂或H2受体拮抗剂进行预防性酸抑制。质子泵抑制剂或H2受体拮抗剂与肾移植受者急性排斥反应、低镁血症及移植肾丢失之间的关联尚不明确。
我们对一个中心的302例肾移植受者进行了一项回顾性队列研究(男性占57%;平均年龄35.5±11.2岁),移植后随访时间超过6个月。根据胃酸预防用药情况将受者分组:仅使用质子泵抑制剂(n = 179)、仅使用H2受体拮抗剂(n = 42)、质子泵抑制剂与H2受体拮抗剂联用(n = 55)以及未使用者(n = 26)。主要结局为活检证实的急性排斥反应。移植肾丢失和低镁血症被定义为次要结局。
与其他研究组相比,未使用者更年轻,且大多处于无类固醇免疫抑制状态(分别为p = 0.030和p = 0.009)。各研究组的主要结局相似(p = 0.266)。Kaplan-Meier分析还显示,10年移植肾生存率相似:质子泵抑制剂组为95.5%,H2受体拮抗剂组为97.6%,质子泵抑制剂/H2受体拮抗剂联用组为100%,未使用者组为96.2%(p = 0.275)。
质子泵抑制剂的使用与急性排斥反应或移植肾丢失无关,但可能导致肾移植受者出现轻度低镁血症。